Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2010

01-05-2010 | Poster presentation

Suppression of the NF-κB co-factor, Bcl3, delays the metastatic progression of breast cancer

Authors: AM Wakefield, RWE Clarkson

Published in: Breast Cancer Research | Special Issue 1/2010

Login to get access

Excerpt

A large proportion of breast cancers overexpress the HER receptors, HER1 or HER2. Generally these patients have a poor prognosis, exhibit resistance to first-line anti-cancer drugs, and frequently develop metastatic disease - the most common cause of patient death. NF-κB transcription factors lie downstream of HER1/2 signalling pathways and are aberrantly activated in the majority of these breast tumours. …
Metadata
Title
Suppression of the NF-κB co-factor, Bcl3, delays the metastatic progression of breast cancer
Authors
AM Wakefield
RWE Clarkson
Publication date
01-05-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2503

Other articles of this Special Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue

Poster presentation

Assessing the functional role of caspase-8 gene variants in breast cancer

Poster presentation

Identification of signalling pathways downstream of BRCA1 and p63

Poster presentation

RhoBTB2 in breast cancer

Lecture presentation

Recent advances in treatment of metastatic breast cancer

Poster presentation

Could side population cells be an indicator of progression to hormone nonresponsive breast cancer

Poster presentation

Phosphoinositide 3-kinase class II beta is a novel target in breast cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits